LONDON – Evidence is mounting that methods based on human cells and computer modeling can provide realistic alternatives to animal toxicology testing. Read More

The drug development graveyard that is sepsis claimed another victim last week, as AZD9773 (CytoFab), which AstraZeneca plc was developing with BTG plc, failed to separate from placebo in a Phase IIb trial in 300 patients with severe sepsis or septic shock. Read More

LONDON – A meta-analysis of cancer patients treated in Phase I studies of targeted drugs has confirmed that there is a much lower risk of the most serious side effects than with traditional chemotherapy. Read More

• Genkyotex SA, of Geneva, reported positive results from studies of GKT137831, for liver fibrosis, showing the ability to attenuate development of fibrosis in the liver and attenuate production of reaction oxygen species in two models of the disease. Read More